The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Expected Market Value Outlook For The Chemotherapy Induced Peripheral Neuropathy Treatment Market Through 2030?
The market size for chemotherapy induced peripheral neuropathy treatment has experienced robust expansion over recent years. This market is projected to expand from $1.75 billion in 2025 to reach $1.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. Historically, this growth can be ascribed to several factors, including the escalating use of neurotoxic chemotherapy agents, improved cancer survival rates, heightened awareness of chemotherapy side effects, the existence of symptomatic treatment options, and the broader development of oncology care infrastructure.
The chemotherapy induced peripheral neuropathy treatment market size is anticipated to undergo significant growth in the forthcoming years. It is forecast to expand to $2.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This projected expansion during the forecast period can be attributed to increased capital allocation towards targeted neuropathy therapies, a growing emphasis on personalized oncology supportive care, the broadening of clinical trials for cipn drugs, an escalating demand for treatments that improve quality of life, and advancements in biomarker-based diagnosis. Key trends for the forecast period encompass an increased focus on neuroprotective drug development, a rising adoption of combination therapy approaches, greater importance placed on early diagnosis and symptom management, the expansion of personalized treatment protocols, and intensified clinical research on cipn management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp
Which Growth Drivers Are Expected To Support The Chemotherapy Induced Peripheral Neuropathy Treatment Market Forward?
The future expansion of the chemotherapy-induced peripheral neuropathy treatment market is anticipated due to the rising incidence of cancer. Cancer defines a condition marked by the unregulated proliferation and dissemination of atypical cells within the body. Chemotherapy-induced peripheral neuropathy represents a possible adverse reaction associated with specific chemotherapy medications administered for cancer therapy. Consequently, the chemotherapy-induced peripheral neuropathy treatment market is poised for expansion driven by the global surge in cancer occurrences. For example, data from July 2024, sourced from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 cases daily, with males constituting approximately 55% of these diagnoses. Hence, the expanding occurrence of cancers is a primary factor fueling the growth of the chemotherapy-induced peripheral neuropathy treatment market.
How Is The Chemotherapy Induced Peripheral Neuropathy Treatment Market Structured Across Different Market Segments?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –
1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics
Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies
What Trends Are Influencing The Future Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
Major companies within the chemotherapy-induced peripheral neuropathy treatment market are concentrating on developing innovative products to enhance their observation power and sustain their market position. For instance, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, announced the FDA’s approval of the Investigational New Drug Application (IND) for ATX01, their Phase 2 first-in-class candidate. This novel treatment is intended for individuals with erythromelalgia. Meanwhile, the first patients in the ATX01 for the Pain of Chemotherapy (ACT) study of chemotherapy-induced peripheral neuropathy (CIPN) have undergone randomization. Both programs have been granted fast-track designation by the FDA.
Which Organizations Are Involved In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.
Access The Complete Chemotherapy Induced Peripheral Neuropathy Treatment Market Report:
What Is The Largest Regional Market In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chemotherapy Induced Peripheral Neuropathy Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=11967&type=smp
Browse Through More Reports Similar to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2026, By The Business Research Company
Chemotherapy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Community Oncology Services Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report
Cancer Supportive Care Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model